✦ LIBER ✦

THE USE OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS FOR DEPRESSION AND PSYCHOSIS COMPLICATING DEMENTIA

✍ Scribed by WILLIAM J. BURKE; VIJAY DEWAN; STEVEN P. WENGEL; WILLIAM H. ROCCAFORTE; GRACE C. NADOLNY; DAVID G. FOLKS

Publisher: John Wiley and Sons
Year: 1997
Tongue: English
Weight: 102 KB
Volume: 12
Category: Article
ISSN: 0885-6230
DOI: 10.1002/(sici)1099-1166(199705)12:5<519::aid-gps534>3.0.co;2-q

No coin nor oath required. For personal study only.

✦ Synopsis

This retrospective chart review examines the impact of selective serotonin reuptake inhibitors on 20 patients with both depression and psychosis complicating dementia of the Alzheimer type (DAT) and other dementias. Fifteen of the 20 patients had moderate to marked improvement in depressive and psychotic symptoms. Eleven of 12 patients with DAT had moderate to marked improvement compared to only four of eight patients with dementia from other causes. The drugs were effective in diminishing or eliminating psychotic symptoms in six patients who had previously not responded to a trial of a neuroleptic. The selective serotonin reuptake inhibitors may have an important role to play in patients with DAT who have coexisting depression and psychosis. These drugs are very well tolerated and may have a place as first-line agents in non-emergent settings where a clinician might otherwise think of instituting a neuroleptic or as a second-line agent when a neuroleptic has proven ineffective.

📜 SIMILAR VOLUMES

‘The use of selective serotonin reuptake

‘The use of selective serotonin reuptake inhibitors for depression and psychosis complicating dementia’—1997, 12, 519–527

✍ Brian Lawlor 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 55 KB 👁 2 views

serotonin syndrome may have been caused by the sum of the serotonergic eects of mirtazapine and ¯uoxetine. The serotonin syndrome appeared despite the concurrent use of chlopromazine, which, by blocking 5-HT1/5-HT2 receptors, was reported to treat it . The same mirtazapine, by blocking 5-HT2/5-HT3 r

Treatment of severe depression with the

Treatment of severe depression with the selective serotonin reuptake inhibitors

✍ Alan F. Schatzberg 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 120 KB 👁 2 views

The selective serotonin reuptake inhibitors (SSRIs) are recognized as effective as and better tolerated than older antidepressant therapies and have become the drugs of choice in the treatment of mild to moderate depression. However, there is a clinical impression that the SSRIs are less effective t

Movement disorders and abuse potential o

Movement disorders and abuse potential of the selective serotonin reuptake inhibitors

✍ B. E. Leonard 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB 👁 2 views

Selective serotonin reuptake inhibitors

Selective serotonin reuptake inhibitors and withdrawal symptoms: a review of the literature

✍ François Therrien; John S. Markowitz 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 175 KB 👁 3 views

There are accumulating reports of withdrawal symptoms emerging following the discontinuation of selective serotonin reuptake inhibitor antidepressants. This report summarizes published reports, characterizes the withdrawal syndrome, discusses potential mechanisms of withdrawal, and makes recommendat

A review of the safety of selective sero

A review of the safety of selective serotonin reuptake inhibitors during pregnancy

✍ David J. Goldstein; Karen Sundell 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB 👁 1 views

Antidepressant treatment may be desirable or necessary during pregnancy; however, the bene®t of treatment must balance the bene®ts to the mother with any risk to the developing fetus. In order to make educated, patient-speci®c, bene®t-to-risk assessments, an understanding of possible risks associate

Milnacipran: The Clinical Properties of

Milnacipran: The Clinical Properties of a Selective Serotonin and Noradrenaline Reuptake Inhibitor (SNRI)

✍ Y. Lecrubier 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 134 KB 👁 1 views

Milnacipran is a novel antidepressant agent which selectively inhibits the reuptake of serotonin and noradrenaline without directly aecting postsynaptic receptor sites. The biochemical and pharmacological pro®le of milnacipran suggested that the drug would be therapeutically eective and well tolerat